A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Incyte Corporation
Incyte Corporation
City of Hope Medical Center
University of Nebraska
Barbara Ann Karmanos Cancer Institute
M.D. Anderson Cancer Center